BACKGROUND:: Recent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of visual disturbances including hallucinations in schizophrenia and Parkinson's disease. METHODS:: To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucinogenic 5-HT2A/1A agonist psilocybin (125 and 250 g/kg vs. placebo) on the spatiotemporal dynamics of modal object completion was assessed in normal volunteers (n = 17) using visual evoked potential recordings in conjunction with topographic-mapping and source analysis. These effects were then considered in relation to the subjective intensity of psilocybin-induced visual hallucinations quantified by psychometric measurement. RESULTS:: Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the P1 component selectively over occipital electrode sites. The decrease of the N170 was most apparent during the processing of incomplete object figures. Moreover, during the time period of the N170, the overall reduction of the activation in the right extrastriate and posterior parietal areas correlated positively with the intensity of visual hallucinations. CONCLUSIONS:: These results suggest a central role of the 5-HT2A/1A-receptors in the modulation of visual processing. Specifically, a reduced N170 component was identified as potentially reflecting a key process of 5-HT2A/1A receptor-mediated visual hallucinations and aberrant modal object completion potential.
Introduction
Despite the fact that the visual and serotonergic systems are among the most explored research topics in neuroscience, there is sparse information about the role of serotonin (5-HT) in visual processing. However, the high expression of the 5-HT1A (1,2) and 5-HT2A receptors (3) (4) (5) in the visual areas V1, V2, V3 and lateral suprasylvian cortex (LS) suggest a central role of the 5-HT1A and 2A receptors in visual processing. Furthermore, 5-HT2A receptors have been implicated in the pathogenesis of visual hallucinations in Parkinson's (6-8) and schizophrenic patients (9) . In support of this view, visual hallucinations in Parkinson's patients have been associated with increased density of 5-HT2A receptors in cortical visual pathways (6, 8) and effectively treated with the 5-HT2A receptor inverse agonist pimavanserin (7) . Moreover, visual disturbances and hallucinations induced by the indoleamine hallucinogen psilocybin are predominantly mediated by the 5-HT2A receptor (10) and resemble, in phenomenological (11) and behavioural measurements (12) , visual disturbances found in schizophrenia (13, 14) . Hence, there is an increasingly recognized role for the 5-HT2A receptors in the pathogenesis of visual hallucinations, while the brain mechanisms mediating between 5-HT2A receptor activation and visual hallucination are still unknown.
To further characterize the role of the 5-HT2A/1A receptors in visual processing and to elucidate possible pathophysiological mechanisms of visual deficits and hallucinations, we assessed the effect of the mixed 5-HT2A/1A agonist psilocybin (125 µg/ and 250 µg/kg vs. placebo) in healthy volunteers. Electroencephalographic recordings were made while participants viewed Kanizsa-and non-Kanizsa-figures ( Figure 1 ). Behavioural responses were recorded and high-density electrical mapping with source-analysis was used. This allowed for measurement of the spatiotemporal brain dynamics of visual modal object completion and its association with the appearance of visual hallucinations.
Modal object completion refers to the illusory perception of object boundaries and their enclosing surface in the absence of any direct sensory information depicting these boundaries or surfaces. The brain's ability to interpolate the existence of object surface boundaries is essential for accurate object recognition in situations where only ambiguous or incomplete retinal information of the object is available (i.e. due to partial occlusion or poor illumination). Modal completion has been of particular interest to vision scientists as it is critical for the accurate perception of objects and the delineation of multiple objects from themselves or their Kometer et al.
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background. Imaging studies provide strong evidence that the intermediate lateral occipital complex (LOC) as well as the early visual area V2 are likely to play a major role in modal completion (15) (16) (17) (18) , while the involvement of the primary visual cortex is more contentious (19) .
Electrophysiological studies revealed that modal object completion of simple figures such as Kanizsa-figures is predominantly indexed by the modulation of the N170 component (20) (21) (22) (23) (24) (25) , which appears to be driven primarily by the two critical processes underlying modal object completion, boundary-completion (22) and region-based-segmentation (25) . In some previous studies the presentation of Kanizsa-figures, compared to control figures, have additionally been associated with an enhancement of the earlier P1 (26) and the subsequent closure negativity (N cl ) component (22) . However, as the N cl component is more reliably induced by more complex fragmented images and reflects successful recognition of complex images (27, 28) it is unlikely to be as relevant to the processing of the simple Kanizsa-figures used in the current experiment.
The high density of 5-HT1A (1,2) and 5-HT2A (3-5) receptors in LOC and V2, as well as the strong activation seen in these areas after psilocybin administration during resting state (29) suggest that psilocybin might influence modal object completion. As these processes are so critical in defining one's perceptual experience, this study aims to characterize and understand the means by which 5-HT2A/1A receptor activity can alter this fundamental aspect of visual experience.
Methods and Materials

Subjects
Healthy right-handed subjects (8 males, 9 females, mean age 28.8 +/-3.5 years) were recruited through advertisement from the University of Zürich. All subjects were healthy according to physical examination including electrocardiography, hematogram and detailed blood analysis.
The DIA-X diagnostic expert system (30) and a clinical interview was used to exclude subjects with present or antecedent psychiatric disorders, regular alcohol or substance abuse and a history of major psychiatric disorders in first degree relatives. The screening procedure was supplemented by the Freiburg Personality Inventory FPI (31) and Hopkins Symptom Checklist SCL-90-R (32) and a self made substance consumption questionnaire. Since the personality trait factor "emotional lability" was identified to be a predictor for negative experiences during hallucinogen-induced altered states of consciousness (33) , scores exceeding the mean value of normative FPI data by two SD were also used as exclusion criterion. Twelve participants reported having previous experience with psilocybin or other hallucinogens (mean life time experiences 5.5 +/-4.7 times). None of the subjects consumed any psychoactive substance except alcohol, nicotine, cannabis and caffeine more than once a year.
After being informed by a written and oral description of the procedures of the study and the effects and possible risks of PY administration, all volunteers gave written informed consent to participate in this study. The study was approved by the ethics committee of the University Hospital of Psychiatry, Zurich, and the use of psilocybin in humans was authorized by the Swiss Federal Office for public health.
Substance and dosing
Psilocybin was obtained through the Swiss Federal Office for Public Health. The psilocybin highdose (HD, 250 mg/kg), low-dose (LD, 125 mg/kg), and lactose placebo (PL) were administered in gelatine capsules of identical number and appearance. On three experimental days, separated from each other by at least two weeks, the subjects came to the lab at 9 am and confirmed they had not eaten breakfast or taken caffeine that morning. In a cross-over randomised design, all subjects received placebo and the two graded doses of psilocybin.
Stimulus and Procedure
The Kanizsa experiment started 120 min post-drug ingestion. During the experiment Kanizsafigures and control figures were presented at a distance of 1 meter from the participants while they remained fixated on a central fixation-cross. All stimuli consisted of three "pacmen", each composed of a black circle with a sector of 60 degrees removed. The removed sectors were either aligned such that the stimulus types induced the perception of an illusory triangle or they were rotated by 180 degrees so as to no longer induce the illusory triangle percept ('Kanizsa' and 'non-Kanizsa' conditions respectively; see Figure 1 ). The stimuli subtended a visual angle of 3.7° and the support ratio, the ratio of the inducing length to the total length of one illusory contour of the triangle, was 1:2. In order to reduce habituation, the stimuli were presented in four different orientations of equal number, rotated 0°, 90°, 180°, and 270°.
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A total of 88 Kanizsa-figures and 88 non-Kanizsa-figures were presented with a stimulus onset asynchrony (SOA) of 3 seconds in a pseudorandomized order in two blocks consisting of 44 Kanizsa-figures and 44 non-Kanizsa-figures each. Participants were required to respond, as quickly as possible, with a button press according to whether or not they saw an illusory triangle on each trial. The response finger was counterbalanced across the subjects to control for faster reaction times of index finger compared to middle finger of the dominant hand. Stimuli remained on the monitor for 300 msec after button-press or for a maximum of 2000 msec.
Psychometry
The Altered States of Consciousness (5D-ASC) rating scale (34) 
EEG recording
EEG recordings were made using BioSemi ActiveTwo electrode system with 64 scalp electrodes.
Additional electrodes were attached on the outer canthus of each eye to record the horizontal electroocculogram (EOG) and infraorbitally and supraorbitally to the left eye to record the vertical EOG. Electrophysiological signals were band-pass filtered at 0.01-67 Hz and digitized at 256 Hz.
EEG analysis
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EEG data were recalculated offline against average reference and band-pass filtered at 1-40 Hz.
Correct response trials were segmented from -150 to +600 ms relative to stimulus presentation.
To avoid eye movement and other artifacts in further analysis, epochs exceeding ±100 µV in any Topographic analysis: First a spatial k-means cluster analysis identified the predominant topographies (also called template map) appearing in the normalized group-averaged ERPs as a function of time and experimental condition (36) . This analysis was constrained by the temporal criterion, that certain topographies must be observed for at least 5 consecutive data points (> 20 ms at a 256 Hz sampling rate). The optimal number of topographies that explained the whole dataset was determined by a modified cross-validation criterion (36) . In a second step we statistically verified that maps identified at the group-averaged level also appeared on the individual subject level. Therefore, at each time point the topography of the individual subjects' ERP was compared by means of strength-independent spatial correlation to all template maps and was labeled according to the one with which it best correlated (35, 37) . This revealed values of Kometer et al. Correlational analyses were performed to determine whether psilocybin-induced changes in the current source density within the time frames defined by topographic analysis were related to visual or auditory hallucinations. First, the differences of the current source density between psilocybin conditions (low-and high-dose) and placebo were calculated separately. In a second step these data were pooled and the product-moment correlations between these differences and the VR and AA scores, respectively, were calculated for each voxel. Significant correlations were identified using nonparametric permutation testing (39) that determined the critical probability threshold values for the observed r-values with correction for multiple testing.
Results
Psychometrics
The subjective effects of psilocybin were assessed by the 5D-ASC rating scale. Repeated measures ANOVA revealed a significant main effect of dose (F(2,32)=36.596, p<0.00001, η 2 =0.70), factor (F(4,64)=12.924, p<0.00001, η 2 =0.45) and dose x factor interaction (F(8,128)=7.09, p<0.00001, η 2 =0.31) . Bonferroni-corrected post-hoc analysis on the VR factor, which was of primary interest in regard to the current study, indicated a significant increase between placebo and low-dose psilocybin (p<0.00001) as well as placebo and high-dose psilocybin (p<0.00001) but not low-dose and high-dose psilocybin (p=0.178). Bonferronicorrected post-hoc analysis on the AA factor revealed a significant increase between placebo and high-dose psilocybin (p<0.05) but not placebo and low-dose psilocybin (p=1.0).
Behavioral data
Reaction time was dose-dependently increased by psilocybin (F(2,32)=18.841, p<0.00001, η 2 =0.54) and was generally faster for Kanizsa-compared to non-Kanizsa- figure (F(1,16) =36.037, p<0.0001, η 2 =0.69) ( Table 1) . While psilocybin administration did lead to a dose-dependent increase in error rates (F(2,32)=3.3291, p<0.05, η 2 =0.17), the error rates remained very low in all conditions (0.88% for placebo, 1.18% for low-dose, 1.92% for high-dose). We are therefore confident that participants were able to do the task under all drug conditions.
Electrophysiological data
Under all 3 drug conditions both stimuli elicited prominent VEP, including the P100 and N170 component ( Figure 1 Kometer et al.
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The source estimation revealed activity within LOC and V2 in both hemispheres in all conditions (Figure 3 ). Current source density was stronger within right-lateralized LOC and V2 in the Kanizsa-compared to non-Kanizsa-condition. Psilocybin dose-dependently decreased the differential activation of the two stimulus conditions and reduced the current source density within LOC, V2 and fusiform gyrus in both stimulus conditions. The psilocybin-induced current source density reduction over right-lateralized LOC, V2 and posterior parietal areas correlated significantly with the increased intensity of visual hallucinations (Figure 4) , while no correlation could be revealed with auditory hallucinations (all Ps > 0.64).
Discussion
The present investigation revealed three main findings. First, the data indicate that the mixed 5- (22) and region-based segmentation (25) , have been shown to underlay the enhanced N170 amplitude in the Kanizsa-condition, it would be interesting to further investigate which of these two sub-processes is modulated by signal transmission at 5-HT2A/1A receptors.
The finding that psilocybin slightly enhanced P1 amplitude may reflect a generalized effect of 5-HT2A/1A mediated increase in perceived brightness which is often reported after indolamine hallucinogen administration (40) . This is supported by previous studies using Kometer et al.
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comparable Kanizsa-figures showing the P1 component to be sensitive to stimulus brightness (41) as well as eccentricity (20) and symmetry (41) .
Given that psilocybin strongly decreased the N170 amplitude in both the Kanizsa and the non-Kanizsa conditions, we suggest that it modulates additional processes beyond proper object completion. Disruption of these processes might play a role in visual hallucinations, since their reported intensity was significantly correlated with the 3-dimensional current source density reduction over right-lateralized LOC, V2 and posterior parietal areas during the time-frame of the N170 component. This localization is in agreement with previous imaging studies reporting decreased extrastriate activation in response to external visual stimuli in patients with visual hallucinations compared to patients without hallucinations (42) (43) (44) . Furthermore, we found decreased activation specifically during the time-range of the N170 component. Decreased activation during this time range has been previously reported in studies investigating acoustic (45, 46) and visual hallucinations (23) . We therefore suggest that decreased stimulus-induced activation in modality-specific cortical areas during the time range of the N1/ N170 component may be a characteristic of acoustic as well as visual hallucinations. This relationship between the increased intensity of visual hallucinations and the decreased stimulus-evoked activation of extrastriate areas during the time-range of the N170 component could reflect a competition for neuronal resources in the processing of internally (hallucination) and externally (sensory-driven) generated information (46, 47) . A comparable mechanism has previously been suggested to be relevant in the formation of acoustic hallucinations (48) . Increased extrastriate activation which could interfere with the processing of external stimuli, has been observed previously during visual hallucinations in the absence of external stimulation in different psychiatric disorders (43, (49) (50) (51) as well as after psilocybin administration (29) . In line with this interpretation we additionally found a correlation between reduced posterior parietal activation and hallucinatory severity. The posterior parietal cortex controls attention to visual stimuli by modulating visual cortex activity (52) during the time-range of the N170 component (53) . The reduced posterior parietal activation might therefore reflect a psilocybin-induced failure to allocate attention and thus neuronal resources to external stimuli. Importantly, we identified reduced extrastriate visual cortex activation during the time range of the N170 as a potential key component of 5-HT2A/1A agonist-induced visual hallucinations. Such a mechanism could also underlie the visual disturbances and hallucinations 12 reported in Parkinson and schizophrenia patients, since increased 5-HT2A receptor densities have been found in these conditions and associated with visual hallucinations (6, 8, 9) . In support of this notion, Parkinson's patients with visual hallucinations showed more pronounced impairments in visual object recognition (54, 55) and more prominent reductions in extrastriate cortex activation to visual stimuli than patients without hallucinations (44) . Moreover, a reduction of the N170 component has also been reported in schizophrenia patients and associated with visual hallucinations using Kanizsa-figures (23) . These observations are in line with our finding of a correlation between reduced extrastriate activation during the time range of the N170 component and the intensity of visual hallucinations. It is noteworthy, however, that two other previous studies using Kanizsa-figures in schizophrenia reported either no reduction (24) or only a reduction at a trend level (56) . The apparent discrepancy between these results and our findings may be due to the fact that only about 30% of schizophrenia patients typically report visual hallucinations (57) and many of the patients tested were medicated with atypical antipsychotics with 5-HT2A antagonistic activity. It might, therefore be possible that a disrupted 5-HT2A receptor system may be relevant only to a subgroup of schizophrenia patients. Given that we did not find a decrease of the P1 component after psilocybin administration and the robust reduction of the P1 component reported in schizophrenia (23, 24, 56, 58) was not associated with psychotic symptoms (58) suggests that the reduction of the P1 component in schizophrenia is not related to serotonergic alterations and may rather represent an endophenotype of the schizophrenia spectrum (58, 59) .
Since psilocybin is a mixed 5-HT2A/1A agonist (60) resulting in downstream effects on the dopamine systems (61), the exact pharmacological mechanisms of the observed psilocybin effects require further investigation. However, converging lines of evidence indicate that psilocybin's psychotomimetic effects are mediated through the 5-HT2A-receptor activation (10, 62) . For example, behavioral effects of psilocybin are lacking in 5-HT2A receptor knockout mice (63) and in humans nearly all psychotomimetic effects including visual distortions and hallucinations can be blocked by the 5-HT2A antagonist ketanserin (64,65), but not by blocking downstream dopaminergic effects with haloperidol (64). These findings, in combination with evidence regarding the importance of the 5-HT2A receptors in the pathophysiology of visual hallucinations (6-9), indicate that the reported effects of psilocybin are likely to be mediated by 5-HT2A receptor activation. However, given that 5-HT1A receptors additionally influence the Kometer et al.
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psychotomimetic effects of indolamine hallucinogens (66) and 5-HT1A receptors are widespread in the visual cortex (1, 2) , further studies are needed to exclude an additional contribution of 5-HT1A receptor on the spatiotemporal dynamics of visual object completion and hallucinations. 
Figure Legends
Figure 4
The voxel-wise correlation between visual hallucinations and placebo -psilocybin current source density difference revealed that psilocybin-induced decrease in current source density in right extrastriate areas and posterior parietal areas over the N170 period (148-223 ms) positively correlated with the intensity of visual hallucinations (significant areas p < 0.05 are shown in red).
194 voxels reached 0.05 significance criterion with a mean r value of 0.57.
